相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban: A New Oral Factor Xa Inhibitor
Elisabeth Perzborn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
C. Weinz et al.
DRUG METABOLISM AND DISPOSITION (2009)
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
D. Lang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
The primary and secondary prevention of coronary artery disease
Richard C. Becker et al.
CHEST (2008)
Antithrombotic therapy in atrial fibrillation
Daniel E. Singer et al.
CHEST (2008)
Antithrombotic therapy for venous thromboembolic disease
Clive Kearon et al.
CHEST (2008)
Pharmacology and management of the vitamin K antagonists
Jack Ansell et al.
CHEST (2008)
Prevention of venous thromboembolism
William H. Geerts et al.
CHEST (2008)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Roger K. Verbeeck
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
G. Rohde
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -: executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster et al.
EUROPEAN HEART JOURNAL (2006)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Limitations of traditional anticoagulants
D Hawkins
PHARMACOTHERAPY (2004)
Coagulation disorders in patients with cirrhosis and severe sepsis
A Plessier et al.
LIVER INTERNATIONAL (2003)
Coagulation disorders in liver disease
L Amitrano et al.
SEMINARS IN LIVER DISEASE (2002)
Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure
ZH Huang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2001)
分享论文
